Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naphthol AS-E phosphate is a synthetic small molecule, chemically known as N-(4-chlorophenyl)-3-(phosphonooxy)naphthalene-2-carboxamide. It is primarily used as a histochemical substrate for alkaline phosphatases and has been studied as an aldolase inhibitor. In cancer research, it acts as an anticancer compound by directly targeting the KIX domain of CBP (CREB-binding protein), thereby disrupting the CREB-CBP complex, inhibiting CREB-target gene induction, and suppressing IL‑1β-mediated angiogenic activity in cancer cell lines. Additionally, it inhibits the activity of transcription factor Myb by blocking its interaction with the KIX domain of coactivator p300 in human leukemia cells. This interference leads to suppression of Myb target genes and induces myeloid differentiation and apoptosis[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphthol AS-E phosphate.